title: Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
abstract: Adrenocortical carcinoma (ACC) is a very rare but aggressive tumor, whose biological and cellular features and processes underlying the development, progression and metastatic evolution are still obscure. Despite many attempts to use general cytostatic and cytotoxic drugs, the only available drug therapy for advanced ACC is still represented by mitotane (MTT). However, the mechanism of action of this adrenolytic derivative of the pesticide DDT has still been poorly characterized. In this context, the development of more specific drugs for ACC treatment is based on the knowledge of the molecular pathways involved in the tumor growth. Xenograft models for the screening of such drugs at preclinical levels is mandatory. In the first part of this review, we will summarize the "pro" and "con" of the different xenograft models available for anticancer drug testing in different types of tumors in general and in the last part, we will focus on the preclinical evidence obtained so far with the use of such models applied to drug screening for anticancer effects in ACC.
authors: Endocrinology Unit, Dept. of Clinical Physiopathology, DENOTHE Center of Excellence for Research, Transfer and High Education, University of Florence, Florence 50139, Italy. m.luconi@dfc.unifi.it
authors: Michaela
authors: M
authors: Luconi
authors: Massimo
authors: M
authors: Mannelli
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D008939:Mitotane / Q000494:pharmacology* / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays / Q000379:methods* / Q000592:standards*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane